En
No inicie tratamiento reductor de la uricemia en pacientes con hiperuricemia asintomática sin síntomas de artritis gotosa ni demostración fehaciente de depósito de urato (tofos)

Brest AN, Heider C, Mehbod H, Onesti G. Drug control of diuretic-induced hyperuricemia. JAMA. 1966;195(1):42-4.

de Vries A, Frank M, Liberman UA, Sperling O. Allopurinol in the prophylaxis of uric acid stones. Annals of the rheumatic diseases. 1966;25(6 Suppl):691-3. Epub 1966/11/01.

Gutman AB, Yu TF. Protracted uricosuric therapy in tophaceous gout. Lancet. 1957;273(7008):1258-60.

Nicotero JA, Scheib ET, Martinez R, Rodnan GP, Shapiro AP. Prevention of hyperuricemia by allopurinol in hypertensive patients treated with chlorothiazide. N Engl J Med. 1970;282(3):133-5.

Yu TF, Gutman AB. Principles of current management of primary gout. Am J Med Sci. 1967;254(6):893-907

Riche-e P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42.

Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2017;56(7):1246